Sernova Biotherapeutics Inc
SVA
Company Profile
Business description
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
Contact
RPO Central Parkway
PO Box 29592
MississaugaONL5A 4H2
CANT: +1 877 299-4603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
8
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,067.15 | 4.57 | 0.06% |
| DAX 40 | 24,505.54 | 197.58 | -0.80% |
| Dow JONES (US) | 48,681.74 | 193.15 | 0.40% |
| FTSE 100 | 10,155.65 | 28.87 | 0.29% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 22,951.58 | 2.74 | -0.01% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,814.49 | 17.63 | 0.26% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |